Aristides Capital LLC Cel Sci Corp Transaction History

Aristides Capital LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.58 - $4.99 $63,029 - $121,905	-24,430 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$7.64 - $12.49 $126,090 - $206,134	-16,504 Reduced 40.32%	24,430 $268,000
Q2 2021 Aug 16, 2021	BUY	$8.68 - $27.49 $104,160 - $329,880	12,000 Added 41.47%	40,934 $355,000
Q1 2021 May 17, 2021	BUY	$12.0 - $27.64 $347,208 - $799,735	28,934 New	28,934 $440,000
Q3 2020 Nov 12, 2020	SELL	$11.69 - $14.54 $298,095 - $370,770	-25,500 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$9.75 - $17.6 $23,322 - $42,099	-2,392 Reduced 8.58%	25,500 $380,000
Q1 2020 May 15, 2020	BUY	$7.54 - $17.05 $210,305 - $475,558	27,892 New	27,892 $322,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Aristides Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Aristides Capital LLC with notifications on news.